Cell Source, Inc.
Cell Source, Inc. (CLCS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
clcs · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cell Source, Inc. (CLCS) measures how much investors pay for each dollar of the company's trailing earnings. CLCS's current PE ratio of N/A is calculated by dividing its stock price of $0.82 by its TTM earnings per share of -$0.11.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2012 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cell Source, Inc.You CLCS | $37M | N/A | — | -$0.11 |
 AccuStem Sciences Limited ACMSY | $0M | N/A | — | -$115.27 |
 Gemina Laboratories Ltd. GLABF | $4M | N/A | — | -$0.03 |
 Hemostemix Inc. HMTXF | $8M | N/A | — | -$0.03 |
 Hadasit Bio-Holdings Ltd HSITF | $1M | N/A | — | -$0.31 |
 Propanc Biopharma, Inc. PPCB | $1M | N/A | — | -$371.22 |
 Quest PharmaTech Inc. QPTFF | $5M | 0.61x | — | $0.03 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-0.11 | — | |
2023-12-31 FY2023 | — | $-0.14 | — | |
2022-12-31 FY2022 | — | $-0.15 | — | |
2021-12-31 FY2021 | — | $-0.19 | — | |
2020-12-31 FY2020 | — | $-0.16 | — | |
2019-12-31 FY2019 | — | $-0.16 | — | |
2018-12-31 FY2018 | — | $-0.08 | — | |
2017-12-31 FY2017 | — | $-0.12 | — | |
2016-12-31 FY2016 | — | $-0.04 | — | |
2015-12-31 FY2015 | — | $-0.10 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cell Source, Inc. (CLCS) measures how much investors pay for each dollar of the company's trailing earnings. CLCS's current PE ratio of N/A is calculated by dividing its stock price of $0.82 by its TTM earnings per share of -$0.11.
Frequently asked questions
CLCS pe ratio · 6 questionsCLCS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.82 and TTM EPS of -$0.11. Data sourced from Financial Modeling Prep via CLCS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cell Source, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09